{"nctId":"NCT01128153","briefTitle":"Saxagliptin Triple Oral Therapy","startDateStruct":{"date":"2010-06"},"conditions":["Type 2 Diabetes"],"count":257,"armGroups":[{"label":"Saxagliptin 5 mg once daily","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin"]},{"label":"Placebo once daily","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Saxagliptin","otherNames":["Onglyza"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written Informed Consent\n* Males or females with type 2 diabetes with inadequate glycaemic control (HbA1c \\> or = 7% and \\< or = 10%) despite being on combination of metformin and sulfonylurea for at least 8 weeks prior to Visit 1\n* BMI \\< or = 40 kg/m2\n\nExclusion Criteria:\n\n* Symptoms of poorly controlled diabetes including but not limited to marked polyuria and marked polydipsia with \\> 10% weight loss in 3 months prior to entry, or other signs and symptoms\n* History of diabetic ketoacidosis or hyperosmolar non-ketotic coma\n* Current or prior use within 3 months of Visit 1 of insulin, DDP4 inhibitor, GLP-1 analogues, and/or other oral anti-diabetic agents (other than metformin or sulfonylurea)\n* Treatment with CYP3A4 inducers and/or potent CYP3A4/5 inhibitor\n* Estimated CrCl \\< 60 ml/min at Visit 2\n* CHF (NYHA class III or IV) and/or LVEF \\<40%\n* Active liver disease and/or significant abnormal liver function defined as AST and/or ALT \\> 3 x ULN and/or bilirubin \\> 2.0 mg/dL at Visit 2.\n* Creatine kinase \\> or = 10 x ULN at Visit 2","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Week 24, Last Observation Carried Forward (LOCF)","description":"Adjusted Mean Change in HbA1c from baseline to Week 24 using analysis of covariance model","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":null},{"groupId":"OG001","value":"-0.08","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in 2-hour Postprandial Glucose (PPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mg/dL]","description":"Adjusted Mean Change in 2-hour PPG from baseline to Week 24 using analysis of covariance model","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.66","spread":null},{"groupId":"OG001","value":"5.08","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in 2-hour Postprandial Glucose (PPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mmol/L]","description":"Adjusted Mean Change in 2-hour PPG from baseline to Week 24 using analysis of covariance model","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.65","spread":null},{"groupId":"OG001","value":"0.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mg/dL]","description":"Adjusted Mean Change in fasting plasma glucose from baseline to Week 24 using analysis of covariance","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.28","spread":null},{"groupId":"OG001","value":"2.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mmol/L]","description":"Adjusted Mean Change in FPG from baseline to Week 24 using analysis of covariance model","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":null},{"groupId":"OG001","value":"0.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Achieving a Therapeutic Response: HbA1c Less Than 7% at Week 24, Last Observation Carried Forward (LOCF)","description":"Number of participants achieving a glycaemic response defined as HbA1c less than 7% at Week 24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":129},"commonTop":["Nasopharyngitis","Diarrhoea","Upper Respiratory Tract Infection","Urinary Tract Infection","Dyslipidaemia"]}}}